Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Zhongguo Fei Ai Za Zhi ; 20(9): 641-644, 2017 Sep 20.
Article in Chinese | MEDLINE | ID: mdl-28935019

ABSTRACT

Adenocarcinoma in situ (AIS) is a new concept which was introduced to the 2011 The International Association for the Study of Cancer (IASLC)/ American Thoracic Society (ATS)/ European Respiratory Society (ERS) International Multidisciplinary Classification of Lung Adenocarcinoma firstly and an important supplement of The 2015 World Health Organization Classification of Lung Tumors. Because AIS is at an early stage of development of lung adenocarcinoma, the deepening understanding of its pathology, differential diagnosis, treatment strategies, has an important significance for the improvement of the prognosis of lung adenocarcinoma. This review will provide a systematic review of the main progress of occurrence and development, pathological characteristics, differential diagnosis and treatment strategy of AIS, in order to provide theoretical basis for the further research of AIS.


Subject(s)
Adenocarcinoma in Situ/diagnosis , Lung Neoplasms/diagnosis , Adenocarcinoma/diagnosis , Adenocarcinoma/drug therapy , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Adenocarcinoma in Situ/drug therapy , Adenocarcinoma in Situ/pathology , Adenocarcinoma in Situ/surgery , Adenocarcinoma of Lung , Animals , Humans , Kaplan-Meier Estimate , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Neoplasm Staging
2.
Int J Gynecol Pathol ; 33(5): 463-9, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25083961

ABSTRACT

The origin of pelvic serous carcinoma continues to be controversial. Recent studies of patients undergoing primary surgery for ovarian, primary peritoneal, and uterine serous carcinomas have indicated the value of complete fimbrial sampling for detecting occult serous tubal intraepithelial carcinoma (STIC). Evidence suggests that a significant proportion of pelvic serous carcinomas may arise from in situ lesions on the distal fallopian tube. In this study, 14 consecutive cases of interval debulking surgery after neoadjuvant chemotherapy were reviewed, using both hematoxylin and eosin staining and, as needed, immunohistochemistry for p53 and MIB-1. The degree of fimbrial sampling was evaluated, and cases were examined for tumor involvement in the endosalpinx and the presence of STIC. Tumor treatment response was classified using a semiquantitative 4-tier scale. The results indicate that STIC can persist despite chemotherapy and can be readily identified during microscopic examination. These results are expected to improve the quality of the pathology evaluation by providing data-driven recommendations for sampling in interval surgery cases and showing the value of a systematic approach to evaluating the fallopian tube (sectioning and extensively examining the fimbria protocol). These results demonstrate that a tubal primary can still be assigned in these situations. Finally, this study raises interesting biologic questions about the sensitivity of cells originating from serous cancer tumor to chemotherapy. The presence or absence of STIC in specimens from interval surgery after neoadjuvant treatment has not previously, to our knowledge, been addressed.


Subject(s)
Adenocarcinoma in Situ/pathology , Cystadenocarcinoma, Serous/pathology , Fallopian Tube Neoplasms/pathology , Fallopian Tubes/pathology , Ovarian Neoplasms/pathology , Peritoneal Neoplasms/pathology , Adenocarcinoma in Situ/drug therapy , Cystadenocarcinoma, Serous/drug therapy , Fallopian Tube Neoplasms/drug therapy , Female , Humans , Neoadjuvant Therapy , Ovarian Neoplasms/drug therapy , Peritoneal Neoplasms/drug therapy , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...